Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
SAN MATEO, Calif., Feb. 06, 2018 -- Adherium (ASX:ADR), a digital health company that improves medication adherence and patient outcomes, will host a conference call on Wednesday, February 7, 2018 at 6:00pm EDT/Thursday, February 8, 2018 at 10:00am AEDT to discuss its Half Year Results to December 31, 2017.
Arik Anderson, Chief Executive Officer will host the call and will be joined by Adherium’s VP Finance and Business Services, Rob Turnbull, and Adherium’s Founder, Garth Sutherland.
Conference Call details:
Conference ID: 6589038
Dial-in Details:
Australia: 1800 123 296 or +61 2 8038 5221
New Zealand: 0800 452 782
Hong Kong: 800 908 865
United States: 1 855 293 1544
Webcast: http://www.openbriefing.com/OB/2812.aspx
For overseas participants, the conference call will commence at:
| - | 12:00pm on Thursday, February 8, 2018 | (New Zealand Daylight Time) | ||
| - | 7:00am on Thursday, February 8, 2018 | (Hong Kong Time) | ||
| - | 3:00pm on Wednesday, February 7, 2018 | (U.S. Pacific Daylight Time) | ||
| - | 6:00pm on Wednesday, February 7, 2018 | (U.S. Eastern Daylight Time) | ||
A recording of the call will be made available in the ‘Investor Centre’ section of the Company website at http://adherium.com/investors/ and at http://www.openbriefing.com/
About Adherium
Adherium is a provider of digital health solutions. The Company develops, manufactures and supplies patients, pharmaceutical companies, healthcare providers and contract research organizations with the broadest range of "smart" medication sensors for respiratory medications to address sub-optimal medication use and improve health outcomes in chronic disease. Adherium is headquartered in the USA, and operates globally from bases in the USA, Europe and Australasia.
Inquiries
United States:
Vik Panda, [email protected]
Leigh Salvo, Gilmartin Group, [email protected], +1 415 937 5404
Europe:
Scott Fleming, [email protected], +31 6 4687 6989
Australia:
Michael Brown, Pegasus Corporate Advisory, +61 400 248 080
Email:
[email protected]
Web:
www.adherium.com
